Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AVEO and Astellas Discontinue Breast Cancer Trial

Published: Friday, January 31, 2014
Last Updated: Friday, January 31, 2014
Bookmark and Share
Joint decision to discontinue trial due to insufficient enrollment.

AVEO Oncology today  announced  that AVEO and Astellas Pharma Inc.  have jointly decided to discontinue the BATON ( Biomarker Assessment of Tivozanib in ONcology ) breast  cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment. AVEO  previously announced that enrollment in this study had been slower than anticipated, and enrollment rates did not improve substantially following additional patient  recruitment efforts.  

“While we believe in the potential benefits of tivozanib for patients with triple  negative breast cancer, we have decided to discontinue the trial because of low patient  accrual,” stated William Slichenmyer, M.D., Sc.M., chief medical officer at AVEO.  “We want to thank the study investigators and their patients who participated in the  trial for their support.” 

The BATON - BC study initiated patient enrollment in December 2012 in a  randomized, double - blind, multicenter Phase 2 clinical trial, evaluating the efficacy of  tivozanib in combination with paclitaxel compared to placebo in combination with  paclitaxel in patients with locally recurrent or metastatic  triple negative breast cancer  who have received no more than one systemic therapy for advanced or metastatic  breast cancer.  All  committed expenses related to the BATON - BC study are shared  equally  between AVEO and  Astellas.  

Separately, as announced in December 2013, data from a planned interim analysis of  the Phase 2 study of tivozanib in patients with colorectal cancer indicate that the study  is unlikely to meet the primary endpoint in the intent - to - treat patient population. Interim data  are being evaluated, and  AVEO and Astellas are in discussions regarding  next steps.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aveo Inks Exclusive Antibody Deal with Novartis
AVEO announces exclusive worldwide license agreement for the development and commercialization of av-380 and related antibodies.
Tuesday, August 18, 2015
AVEO Granted Patent for Predictive Biomarker Used to Identify Human Tumors Likely to Respond to Notch Pathway Inhibition
Discovery of HeyL gene expression as biomarker marks critical step in developing targeted therapeutics to inhibit notch pathway.
Thursday, June 18, 2009
AVEO Initiates First Clinical Trial of Novel HGF Antagonist
AVEO initiates first clinical trial of novel HGF antagonist in patients with advanced solid tumors and lymphomas.
Wednesday, September 24, 2008
Human Tissue Transgenic Cancer Model may Offer Significant Advance Toward Modeling Human Cancer
AVEO Pharmaceuticals has created invasive human tumors that develop over time in mice from primary human breast tissue.
Thursday, April 19, 2007
Scientific News
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Improving Regenerative Medicine
Lab-created stem cells may lack key characteristics, UCLA research finds.
Tick Genome Reveals Secrets of a Successful Bloodsucker
NIH has announced that decipher the genome of the blacklegged tick which could lead to new tick control methods.
"Dark Side" of the Transcriptome
New approach to quantifying gene "read-outs" reveals important variations in protein synthesis and has implications for understanding neurodegenerative diseases.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
New Source of Mutations in Cancer
Recently, a new mutation signature found in cancer cells was suspected to have been created by a family of enzymes found in human cells called the APOBEC3 family.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!